Craig supports the growth of Life Science businesses from an operational perspective, helping them scale up and function effectively. He brings more than 20 years of drug discovery and development experience, with extensive experience as a research scientist managing projects from initial target selection through to Phase 2 clinical studies.

He joined Oxford Science Enterprises in February 2022 from C4X Discovery, where he was Chief Scientific Officer and an Executive Board Member for over six years, guiding its transition from a technology-based company to a therapeutics business. Craig has also worked at several biotech companies, supporting financing rounds, strategic collaborations and licensing deals with Pharma.

Craig holds a PhD in Respiratory Medicine from Birmingham University and a first-class Biochemistry degree from the University of Surrey.